CORRECTING and REPLACING Arrowhead Appoints Patrick O’Brien as General Counsel
PASADENA, Calif.–(BUSINESS WIRE)–
Arrowhead Research Corporation corrects its press release issued on
December 4, 2014, to correct the statement regarding “inducement” grants.
The corrected release reads:
ARROWHEAD APPOINTS PATRICK O’BRIEN AS GENERAL COUNSEL
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical
company developing targeted RNAi therapeutics, today announced that it
has appointed Patrick O’Brien as General Counsel. In this role, Mr.
O’Brien will have overall responsibility to manage all of the Company’s
legal matters.
“Patrick will be an integral part of the Arrowhead management team,”
said Christopher Anzalone, Ph.D., Arrowhead’s President and Chief
Executive Officer. “His twenty year history of representing and advising
biopharmaceutical companies from multiple vantage points will be a great
asset as we move forward.”
Mr. O’Brien comes to Arrowhead from Shire where he served as Group Vice
President, Legal in Shire’s Boston office. Prior to that, he was Chief
Legal Officer for Shire’s regenerative medicine division. Mr. O’Brien
has also served as Assistant General Counsel for Johnson & Johnson and
Vice President, Law of its Centocor Ortho-Biotech business unit,
Regulatory Counsel at the U.S. Food and Drug Administration, and as
outside counsel to biopharmaceutical high technology companies while
engaged in private practice. He holds B.S. in Pharmacy, Pharm.D., and
J.D. degrees from the University of Arizona.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary
Dynamic Polyconjugate delivery platform to develop targeted drugs based
on the RNA interference mechanism that efficiently silences
disease-causing genes. Arrowhead’s pipeline includes ARC-520 for chronic
hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1
antitrypsin deficiency, and partner-based programs in obesity and
oncology.
For more information please visit http://www.arrowheadresearch.com,
or follow us on Twitter @ArrowRes.
To be added to the Company’s email list and receive news directly,
please visit http://ir.arrowheadresearch.com/alerts.cfm.
NASDAQ Notice
As an inducement to entering into employment with the Company, on
December 2, 2014, Patrick O’Brien and one other new employee of the
Company were awarded “inducement” grants of options and restricted stock
units (RSU) under Rule 5635(c)(4) of the NASDAQ Marketplace Rules. The
option grants entitle Mr. O’Brien to purchase up to 90,000 shares of
common stock and the other employee to purchase up to 30,000 shares of
common stock, in each case outside of the Company’s stockholder-approved
equity incentive plans at an exercise price per share of $5.22, the last
reported closing price of the Company’s common stock on the date of
grant. Additionally, Mr. O’Brien was awarded 30,000 restricted stock
units outside of the Company’s stockholder-approved equity incentive
plans. The options vest and become exercisable over a period of four
years from the date of grant and the RSUs vest annually in three equal
installments.
Source: Arrowhead Research Corporation
Arrowhead Research Corporation
Vince Anzalone, CFA
626-304-3400
ir@arrowres.com
or
Investor
Relations:
The Trout Group
Lauren Glaser
646-378-2972
ir@arrowres.com
or
Media:
Russo
Partners
Martina Schwarzkopf, Ph.D.
212-845-4292
martina.schwarzkopf@russopartnersllc.com
Source: Arrowhead Research Corporation
News Provided by Acquire Media